Individualizing Treatment for Asthma in Primary Care

PHASE4CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions
AsthmaBronchial DiseasesRespiratory Tract InfectionsLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityImmune System Diseases
Interventions
OTHER

Asthma Symptom Monitoring online tools

All participants will be provided access to the Asthma Symptom Monitoring tools and 3/4's will be randomized to one of the other three arms above

DRUG

Inhaled Steroids

participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice with their current reliever therapy or be converted to budesonide/albuterol as rescue therapy

DRUG

Azithromycin Pill

Participants will take 500mg of azithromycin three times a week or 10mg/kg if under 50Kg which may be reduced to 250mg/Kg for side effects

Trial Locations (1)

80045

DARTNet Insitute, Aurora

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Penn State University

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

University of Colorado, Denver

OTHER

collaborator

RAND

OTHER

collaborator

University of Washington

OTHER

collaborator

Rutgers University

OTHER

collaborator

University of North Carolina

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Reliant Medical Group

OTHER

collaborator

Kelsey Research Foundation

OTHER

collaborator

Wake Forest University Health Sciences

OTHER

lead

DARTNet Institute

OTHER_GOV

NCT06272370 - Individualizing Treatment for Asthma in Primary Care | Biotech Hunter | Biotech Hunter